Group 1 - The core viewpoint of the article is that as of August 22, 2025, institutional investors hold a total of 529 million shares of Jinjia Co., accounting for 36.45% of the company's total share capital, with a slight decrease of 0.63 percentage points compared to the previous quarter [1] Group 2 - Six institutional investors have disclosed their holdings in Jinjia Co., including Shenzhen Jinjia Venture Capital Co., Xinjiang Century Yuntong Equity Investment Partnership, Hong Kong Central Clearing Limited, Fujian Lexiang Investment Co., Morgan Stanley & Co. International PLC, and Hongde Yuexiang One-Year Holding Period Mixed A [1] - One new public fund has been disclosed this period, which is Hongde Yuexiang One-Year Holding Period Mixed A, while two public funds, Southern CSI 1000 ETF and Huaxia CSI 1000 ETF, were not disclosed in this period [1] - One social security fund, the National Social Security Fund 503 Portfolio, was not disclosed in this period compared to the previous quarter [1] - Foreign investment sentiment shows an increase in holdings from one foreign fund, Hong Kong Central Clearing Limited, with an increase of 0.48% [1]

Core Viewpoint - Fengyuan Pharmaceutical (000153.SZ) released its semi-annual report for 2025, indicating a total institutional holding of 141 million shares, accounting for 30.39% of the company's total equity, with a slight decrease of 0.36 percentage points from the previous quarter [1] Institutional Holdings - As of August 21, 2025, seven institutional investors disclosed their holdings in Fengyuan Pharmaceutical, with a combined shareholding of 141 million shares [1] - The institutional investors include Anhui Wuwei Pharmaceutical Factory, Bengbu Tushan Enterprise Management Co., Ltd., Ma'anshan Fengyuan Enterprise Management Co., Ltd., Anhui Fengyuan Group Co., Ltd., Great Wall Guorong Investment Management Co., Ltd., BARCLAYS BANK PLC, and Guojin 300 Index Enhanced A [1] - The total institutional holding percentage decreased by 0.36 percentage points compared to the previous quarter [1] Public Fund and Foreign Investment - One new public fund disclosed its holdings this period, namely Guojin 300 Index Enhanced A [1] - Two public funds that were previously disclosed did not report this quarter, including Guojin CSI A500 Index Enhanced A and Dongxing Lianzhong One-Year Holding Period Mixed A [1] - One new foreign institution disclosed its holdings, BARCLAYS BANK PLC, while MORGAN STANLEY & CO. INTERNATIONAL PLC was not reported this quarter [1]

Group 1 - Anke Bio (300009.SZ) released its semi-annual report for 2025 on August 22, 2025, showing that as of August 21, 2025, 12 institutional investors held a total of 81.64 million shares, accounting for 4.88% of the total share capital [1] - The top ten institutional investors include Hong Kong Central Clearing Limited, Bank of China - CMB National Bio-Medicine Index Fund, Shanghai Bank - Yinhua CSI Innovative Drug Industry ETF, and others, with a combined holding ratio of 4.88%, which decreased by 0.62 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, three funds reduced their holdings compared to the previous quarter, including the Innovative Drug Fund and CMB National Bio-Medicine Index A, with a reduction ratio of 0.31% [2] - Seven new public funds were disclosed this period, including Southern CSI 1000 ETF and various funds from Fortune, while two funds were no longer disclosed compared to the previous quarter [2] - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.44% compared to the previous period [2]

Core Insights - Capital Online (300846.SZ) released its semi-annual report for 2025, revealing that as of August 21, 2025, five institutional investors disclosed holdings in Capital Online A-shares, totaling 7.1835 million shares, which represents 1.43% of the total share capital [1] - The overall institutional holding percentage decreased by 0.60 percentage points compared to the previous quarter [1] Institutional Holdings - The institutional investors include Hong Kong Central Clearing Limited, Minqing County Lianyu Enterprise Management Center (Limited Partnership), Abu Dhabi Investment Authority, MORGAN STANLEY & CO. INTERNATIONAL PLC., and Jin Xin Quantitative Selected Mixed A [1] - One public fund, Jin Xin Quantitative Selected Mixed A, reported a slight decrease in holdings compared to the previous quarter [1] - One public fund, Yongying Technology Smart Selection Mixed Initiation A, was not disclosed in the current period compared to the previous quarter [1] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, reported a decrease in holdings, with a reduction percentage of 0.65% compared to the previous quarter [1] - A new foreign institution, Abu Dhabi Investment Authority, disclosed its holdings in the current period [1] - MORGAN STANLEY & CO. INTERNATIONAL PLC. was not disclosed in the current period compared to the previous quarter [1]

Core Insights - International Medicine (000516.SZ) released its semi-annual report for 2025, indicating that as of August 21, 2025, six institutional investors held a total of 742 million shares, representing 33.14% of the company's total equity [1] - The institutional holding percentage decreased by 0.46 percentage points compared to the previous quarter [1] - Four public funds were disclosed this period, including Huatai-PineBridge Healthcare Active Growth One-Year Holding Mixed A, Golden Eagle Strategy Allocation Mixed, GF Asset Management Prosperity Selection Mixed A, and Zheshang Huijin Transformation Driven [1] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.29% compared to the previous quarter [1]

Group 1 - The Saudi Public Investment Fund (PIF) has liquidated its holdings in several U.S. listed companies during the second quarter, including Alibaba, Meta, FedEx, Shopify, PayPal, and Nu Holdings, no longer holding any shares in these companies [1] - As of the end of the first quarter, PIF held 667,996 Class A shares of Meta, 1.61 million American Depositary Shares (ADS) of Alibaba, and 498,164 common shares of FedEx [1] - The U.S. stock market experienced a decline in April due to tariff policy impacts but rebounded thereafter during the second quarter [1]

Group 1 - The core viewpoint of the news is that Tongchen Beijian (300146.SZ) reported its semi-annual results for 2025, revealing a total of 1.07 billion shares held by institutional investors, accounting for 6.27% of the company's total equity [1] - As of August 8, 2025, there are 9 institutional investors holding shares in Tongchen Beijian, with a slight decrease of 0.09 percentage points in institutional holding compared to the previous quarter [1] - The institutional investors include various funds such as E Fund's ChiNext ETF and Hong Kong Central Clearing Limited, indicating a diverse investment base [1] Group 2 - In the public fund sector, 4 funds increased their holdings, with a total increase of 0.12% compared to the previous period [2] - One public fund, E Fund's ChiNext ETF, reported a slight decrease in holdings, while one fund, Huatai-PineBridge's major consumption ETF, did not disclose holdings this period [2] - Foreign investment sentiment showed a decrease in holdings from Hong Kong Central Clearing Limited, with a reduction of 0.13% compared to the previous quarter [2]

Core Viewpoint - Enhua Pharmaceutical (002262.SZ) reported its semi-annual results for 2025, highlighting significant institutional investment and changes in public fund holdings [1][2]. Institutional Holdings - As of July 29, 2025, 22 institutional investors disclosed holdings in Enhua Pharmaceutical, totaling 374 million shares, which represents 36.83% of the company's total equity [1]. - The top ten institutional investors collectively hold 36.56% of the shares, with a slight increase of 0.09 percentage points compared to the previous quarter [1]. Public Fund Holdings - Three public funds reduced their holdings compared to the previous quarter, with a total decrease of 0.42% [2]. - Twelve new public funds disclosed holdings in Enhua Pharmaceutical, including notable names such as Southern CSI 500 ETF and Dachen Active Growth Mixed A [2]. - Fifteen public funds that previously held shares did not disclose their holdings this quarter, including several healthcare-focused funds [2]. Social Security Fund - One new social security fund, the National Social Security Fund 406 Combination, disclosed its holdings in Enhua Pharmaceutical during this period [2]. Insurance Capital - One insurance company, China Life Insurance Co., Ltd. - Traditional - Ordinary Insurance Product - 005L-CT001, increased its holdings by 0.2% compared to the previous period [2]. Foreign Investment - One foreign institution, Hong Kong Central Clearing Limited, did not disclose its holdings this quarter, indicating a potential shift in foreign investment interest [3].

Group 1 - The core viewpoint of the news is the disclosure of institutional and public fund holdings in China Wuyi, indicating a significant concentration of ownership among a few major investors [1][2] - As of April 18, 2025, a total of 22 institutional investors hold shares in China Wuyi, amounting to 893 million shares, which represents 56.86% of the total share capital [1] - The top ten institutional investors collectively hold 56.83% of the shares, with a slight decrease of 0.60 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, the Southern CSI All Index Real Estate ETF, reported a decrease in holdings, accounting for a reduction of 0.27% [2] - A total of 17 new public funds were disclosed this quarter, including major funds such as CSI 2000 and Huaxia CSI All Index Real Estate ETF [2] - One foreign fund, Hong Kong Central Clearing Limited, also reported a slight decrease in holdings compared to the previous quarter [2]